Review of immune therapy in HCC: Where are we now and what is the future?

Competing Interests: Lorenza Rimassa consults for, is on the speakers’ bureau for, and received grants from AstraZeneca, Eisai, Incyte, Ipsen, Roche, and Servier. She consults for and is on the speakers’ bureau for Bayer and BMS. She consults for and received grants from Exelixis, MSD, Nerviano Medical Sciences, and Zymeworks. She consults for Basilea, Elevar Therapeutics, Genenta, Hengrui, IQVIA, Jazz Pharmaceuticals, and Taiho Oncology. She is on the speakers’ bureau for Merck Serono. She received grants from Agios, BeiGene, Fibrogen, and Lilly. The remaining authors have no conflicts to report.